{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:10:13Z","timestamp":1788930613009,"version":"build-2803163510"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03326-2","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:58:45Z","timestamp":1784185125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Hannah H.","family":"Rashwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan M. E.","family":"Azzazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"29","key":"3326_CR1","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","volume":"23","author":"JD Brenton","year":"2005","unstructured":"Brenton JD, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J Clin Oncol. 2005;23(29):7350\u201360.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3326_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3326_CR3","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E. Subtypes of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU); 2022.","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"2","key":"3326_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176\u201398.","journal-title":"Cancer Discov"},{"issue":"31","key":"3326_CR5","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3326_CR6","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.5858\/134.7.e48","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48\u201372.","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"3326_CR7","first-page":"101","volume":"21","author":"AK Dogra","year":"2025","unstructured":"Dogra AK, et al. Prognostic significance and molecular classification of triple negative breast cancer: a systematic review. Eur J Breast Health. 2025;21(2):101\u201314.","journal-title":"Eur J Breast Health"},{"issue":"3","key":"3326_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217\u201326.","journal-title":"N Engl J Med"},{"issue":"16","key":"3326_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"22","key":"3326_CR10","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463\u201372.","journal-title":"Cancer"},{"key":"3326_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/srep00227","volume":"2","author":"RM Hallett","year":"2012","unstructured":"Hallett RM, et al. A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep. 2012;2:227.","journal-title":"Sci Rep"},{"issue":"6","key":"3326_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto M, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19(6):608\u201315.","journal-title":"Oncologist"},{"issue":"1","key":"3326_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.18632\/oncotarget.12284","volume":"8","author":"H Yao","year":"2017","unstructured":"Yao H, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913\u201324.","journal-title":"Oncotarget"},{"issue":"11","key":"3326_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"3326_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314937","author":"E Kudelova","year":"2022","unstructured":"Kudelova E, et al. Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232314937.","journal-title":"Int J Mol Sci"},{"key":"3326_CR16","first-page":"113","volume":"17","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang R, Li D. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer. Biologics. 2023;17:113\u201328.","journal-title":"Biologics"},{"issue":"10","key":"3326_CR17","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230034","volume":"43","author":"BE Adrada","year":"2023","unstructured":"Adrada BE, et al. Triple-negative breast cancer: histopathologic features, genomics, and treatment. Radiographics. 2023;43(10):e230034.","journal-title":"Radiographics"},{"issue":"6","key":"3326_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14796694.2025.2461443","volume":"21","author":"A Jan","year":"2025","unstructured":"Jan A, et al. An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Future Oncol. 2025;21(6):715\u201335.","journal-title":"Future Oncol"},{"issue":"3","key":"3326_CR19","doi-asserted-by":"publisher","first-page":"201008","DOI":"10.1016\/j.omton.2025.201008","volume":"33","author":"FP Oliveira","year":"2025","unstructured":"Oliveira FP, et al. Translational drugs targeting cancer stem cells in triple-negative breast cancer. Mol Ther Oncol. 2025;33(3):201008.","journal-title":"Mol Ther Oncol"},{"key":"3326_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133287","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Breast cancer stem cells: signaling pathways, cellular interactions, and therapeutic implications. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14133287.","journal-title":"Cancers (Basel)"},{"key":"3326_CR21","doi-asserted-by":"publisher","first-page":"1199105","DOI":"10.3389\/fonc.2023.1199105","volume":"13","author":"N Srivastava","year":"2023","unstructured":"Srivastava N, et al. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Front Oncol. 2023;13:1199105.","journal-title":"Front Oncol"},{"key":"3326_CR22","doi-asserted-by":"publisher","first-page":"1633845","DOI":"10.3389\/fimmu.2025.1633845","volume":"16","author":"G Almanzar","year":"2025","unstructured":"Almanzar G, et al. Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease - a link between cancer and autoimmunity. Front Immunol. 2025;16:1633845.","journal-title":"Front Immunol"},{"issue":"20","key":"3326_CR23","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.3390\/ijms26209902","volume":"26","author":"A Szulc","year":"2025","unstructured":"Szulc A, Wozniak M. Targeting ferroptosis as the Achilles\u2019 Heel of breast cancer: mechanisms and therapeutic opportunities from a comprehensive systematic review. Int J Mol Sci. 2025;26(20):9902.","journal-title":"Int J Mol Sci"},{"key":"3326_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071796.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3326_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"3326_CR26","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.2011.38.2010","volume":"30","author":"O Metzger-Filho","year":"2012","unstructured":"Metzger-Filho O, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879\u201387.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3326_CR27","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","volume":"149","author":"A Mandapati","year":"2023","unstructured":"Mandapati A, Lukong KE. Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol. 2023;149(7):3701\u201319.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6797","key":"3326_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"1","key":"3326_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41523-021-00270-4","volume":"7","author":"GA Patwardhan","year":"2021","unstructured":"Patwardhan GA, et al. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. NPJ Breast Cancer. 2021;7(1):60.","journal-title":"NPJ Breast Cancer"},{"key":"3326_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040916","author":"E Vagia","year":"2020","unstructured":"Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040916.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3326_CR31","first-page":"517","volume":"4","author":"Y Zong","year":"2021","unstructured":"Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resist. 2021;4(3):517\u201342.","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"3326_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","volume":"13","author":"TA Moo","year":"2018","unstructured":"Moo TA, et al. Overview of Breast Cancer Therapy. PET Clin. 2018;13(3):339\u201354.","journal-title":"PET Clin"},{"key":"3326_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168844","author":"N Jinna","year":"2022","unstructured":"Jinna N, et al. Adaptation to hypoxia may promote therapeutic resistance to androgen receptor inhibition in triple-negative breast cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23168844.","journal-title":"Int J Mol Sci"},{"key":"3326_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020483","author":"SM Banerjee","year":"2020","unstructured":"Banerjee SM, et al. Photodynamic therapy in primary breast cancer. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9020483.","journal-title":"J Clin Med"},{"issue":"5","key":"3326_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1445-2197.1991.tb00230.x","volume":"61","author":"MD Daniell","year":"1991","unstructured":"Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991;61(5):340\u20138.","journal-title":"Aust N Z J Surg"},{"issue":"4","key":"3326_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/photochem4040027","volume":"4","author":"Y Allamyradov","year":"2024","unstructured":"Allamyradov Y, et al. Photodynamic Therapy Review: Past, Present, Future, Opportunities and Challenges. Photochem. 2024;4(4):434\u201361.","journal-title":"Photochem"},{"key":"3326_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/276109","volume":"2008","author":"LB Josefsen","year":"2008","unstructured":"Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs. 2008;2008:276109.","journal-title":"Met Based Drugs"},{"issue":"4","key":"3326_CR38","first-page":"250","volume":"61","author":"P Agostinis","year":"2011","unstructured":"Agostinis P, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250\u201381.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3326_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrc1071","volume":"3","author":"DE Dolmans","year":"2003","unstructured":"Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380\u20137.","journal-title":"Nat Rev Cancer"},{"key":"3326_CR40","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","volume":"106","author":"S Kwiatkowski","year":"2018","unstructured":"Kwiatkowski S, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098\u2013107.","journal-title":"Biomed Pharmacother"},{"key":"3326_CR41","doi-asserted-by":"publisher","first-page":"1476228","DOI":"10.3389\/fphar.2024.1476228","volume":"15","author":"Y Hua","year":"2024","unstructured":"Hua Y, et al. Applications and challenges of photodynamic therapy in the treatment of skin malignancies. Front Pharmacol. 2024;15:1476228.","journal-title":"Front Pharmacol"},{"key":"3326_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jare.2025.01.042","volume":"77","author":"C Liang","year":"2025","unstructured":"Liang C, et al. Hypericin photoactivation induces triple-negative breast cancer cells pyroptosis by targeting the ROS\/CALR\/Caspase-3\/GSDME pathway. J Adv Res. 2025;77:669\u201388.","journal-title":"J Adv Res"},{"key":"3326_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910506","author":"DR Mokoena","year":"2021","unstructured":"Mokoena DR, George BP, Abrahamse H. Photodynamic therapy induced cell death mechanisms in breast cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910506.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3326_CR44","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.ijrobp.2004.08.006","volume":"61","author":"B Chen","year":"2005","unstructured":"Chen B, et al. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys. 2005;61(4):1216\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11\u201312","key":"3326_CR45","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/sj.bjc.6690271","volume":"79","author":"VH Fingar","year":"1999","unstructured":"Fingar VH, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer. 1999;79(11\u201312):1702\u20138.","journal-title":"Br J Cancer"},{"key":"3326_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/1471-2407-10-235","volume":"10","author":"Z Hu","year":"2010","unstructured":"Hu Z, et al. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer. 2010;10:235.","journal-title":"BMC Cancer"},{"issue":"1","key":"3326_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0304-3835(01)00475-X","volume":"167","author":"K Kurohane","year":"2001","unstructured":"Kurohane K, et al. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 2001;167(1):49\u201356.","journal-title":"Cancer Lett"},{"issue":"1","key":"3326_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5411\/wji.v4.i1.1","volume":"4","author":"E Reginato","year":"2014","unstructured":"Reginato E, Wolf P, Hamblin MR. Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects. World J Immunol. 2014;4(1):1\u201311.","journal-title":"World J Immunol"},{"issue":"1","key":"3326_CR49","doi-asserted-by":"publisher","first-page":"1600106","DOI":"10.1002\/advs.201600106","volume":"4","author":"D Luo","year":"2017","unstructured":"Luo D, et al. Chemophototherapy: An Emerging Treatment Option for Solid Tumors. Adv Sci (Weinh). 2017;4(1):1600106.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3326_CR50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5946\/ce.2013.46.1.24","volume":"46","author":"RR Allison","year":"2013","unstructured":"Allison RR, Moghissi K. Photodynamic Therapy (PDT): PDT Mechanisms. Clin Endosc. 2013;46(1):24\u20139.","journal-title":"Clin Endosc"},{"issue":"7","key":"3326_CR51","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/lsm.21080","volume":"43","author":"GB Kharkwal","year":"2011","unstructured":"Kharkwal GB, et al. Photodynamic therapy for infections: clinical applications. Lasers Surg Med. 2011;43(7):755\u201367.","journal-title":"Lasers Surg Med"},{"issue":"12","key":"3326_CR52","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/jnci\/90.12.889","volume":"90","author":"TJ Dougherty","year":"1998","unstructured":"Dougherty TJ, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889\u2013905.","journal-title":"J Natl Cancer Inst"},{"key":"3326_CR53","doi-asserted-by":"publisher","first-page":"863107","DOI":"10.3389\/fonc.2022.863107","volume":"12","author":"L Tan","year":"2022","unstructured":"Tan L, et al. The Role of Photodynamic Therapy in Triggering Cell Death and Facilitating Antitumor Immunology. Front Oncol. 2022;12:863107.","journal-title":"Front Oncol"},{"issue":"1","key":"3326_CR54","first-page":"53","volume":"59","author":"A Nowak-Stepniowska","year":"2013","unstructured":"Nowak-Stepniowska A, Pergol P, Padzik-Graczyk A. Photodynamic method of cancer diagnosis and therapy\u2013mechanisms and applications]. Postepy Biochem. 2013;59(1):53\u201363.","journal-title":"Postepy Biochem"},{"issue":"12","key":"3326_CR55","first-page":"1137","volume":"39","author":"Z Luksiene","year":"2003","unstructured":"Luksiene Z. Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment. Med (Kaunas). 2003;39(12):1137\u201350.","journal-title":"Med (Kaunas)"},{"issue":"1","key":"3326_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1572-1000(05)00030-X","volume":"2","author":"AP Castano","year":"2005","unstructured":"Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2005;2(1):1\u201323.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"3","key":"3326_CR57","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.apsb.2023.11.007","volume":"14","author":"L Yu","year":"2024","unstructured":"Yu L, et al. Towards overcoming obstacles of type II photodynamic therapy: Endogenous production of light, photosensitizer, and oxygen. Acta Pharm Sin B. 2024;14(3):1111\u201331.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3326_CR58","first-page":"100775","volume":"18","author":"X Li","year":"2023","unstructured":"Li X, et al. Innovative strategies for photodynamic therapy against hypoxic tumor. Asian J Pharm Sci. 2023;18(1):100775.","journal-title":"Asian J Pharm Sci"},{"issue":"2","key":"3326_CR59","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1039\/C7SC03765A","volume":"9","author":"Z Lv","year":"2018","unstructured":"Lv Z, et al. Achieving efficient photodynamic therapy under both normoxia and hypoxia using cyclometalated Ru(ii) photosensitizer through type I photochemical process. Chem Sci. 2018;9(2):502\u201312.","journal-title":"Chem Sci"},{"issue":"22","key":"3326_CR60","doi-asserted-by":"publisher","first-page":"16341","DOI":"10.1021\/acs.inorgchem.0c02137","volume":"59","author":"JA Roque III","year":"2020","unstructured":"Roque III JA, et al. Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy. Inorg Chem. 2020;59(22):16341\u201360.","journal-title":"Inorg Chem"},{"issue":"23","key":"3326_CR61","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.1039\/C6CS00616G","volume":"45","author":"W Fan","year":"2016","unstructured":"Fan W, Huang P, Chen X. Overcoming the Achilles\u2019 heel of photodynamic therapy. Chem Soc Rev. 2016;45(23):6488\u2013519.","journal-title":"Chem Soc Rev"},{"issue":"7","key":"3326_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.603","volume":"5","author":"W Zhao","year":"2020","unstructured":"Zhao W, et al. Photodynamic therapy for cancer: mechanisms, photosensitizers, nanocarriers, and clinical studies. MedComm (2020). 2020;5(7):e603.","journal-title":"MedComm (2020)"},{"issue":"2","key":"3326_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1572-1000(05)00060-8","volume":"2","author":"AP Castano","year":"2005","unstructured":"Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther. 2005;2(2):91\u2013106.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"46","key":"3326_CR64","doi-asserted-by":"publisher","first-page":"81591","DOI":"10.18632\/oncotarget.20189","volume":"8","author":"J Kou","year":"2017","unstructured":"Kou J, Dou D, Yang L. Porphyrin photosensitizers in photodynamic therapy and its applications. Oncotarget. 2017;8(46):81591\u2013603.","journal-title":"Oncotarget"},{"issue":"1","key":"3326_CR65","doi-asserted-by":"publisher","first-page":"BR47","DOI":"10.12659\/MSM.882203","volume":"18","author":"E Szliszka","year":"2012","unstructured":"Szliszka E, et al. Chlorin-based photodynamic therapy enhances the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in bladder cancer cells. Med Sci Monit. 2012;18(1):BR47\u201353.","journal-title":"Med Sci Monit"},{"issue":"30","key":"3326_CR66","doi-asserted-by":"publisher","first-page":"38916","DOI":"10.1021\/acsami.4c05181","volume":"16","author":"J Bonelli","year":"2024","unstructured":"Bonelli J, et al. A Nanoencapsulated Ir(III)-Phthalocyanine Conjugate as a Promising Photodynamic Therapy Anticancer Agent. ACS Appl Mater Interfaces. 2024;16(30):38916\u201330.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3326_CR67","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41420-024-02236-4","volume":"10","author":"G Li","year":"2024","unstructured":"Li G, et al. Advances in smart nanotechnology-supported photodynamic therapy for cancer. Cell Death Discov. 2024;10(1):466.","journal-title":"Cell Death Discov"},{"issue":"3","key":"3326_CR68","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-024-07607-0","volume":"210","author":"CR Silva","year":"2025","unstructured":"Silva CR, et al. Photodynamic therapy as a strategic ally in radiotherapy for triple-negative breast cancer: the importance of treatment order. Breast Cancer Res Treat. 2025;210(3):687\u201397.","journal-title":"Breast Cancer Res Treat"},{"key":"3326_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030580","author":"JI Traylor","year":"2021","unstructured":"Traylor JI, et al. Molecular and metabolic mechanisms underlying selective 5-aminolevulinic acid-induced fluorescence in gliomas. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030580.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3326_CR70","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/php.12454","volume":"91","author":"X Yang","year":"2015","unstructured":"Yang X, et al. Effects of silencing heme biosynthesis enzymes on 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy. Photochem Photobiol. 2015;91(4):923\u201330.","journal-title":"Photochem Photobiol"},{"issue":"Suppl 3","key":"3326_CR71","first-page":"S34112","volume":"30","author":"BW Pogue","year":"2025","unstructured":"Pogue BW, et al. Emerging uses of 5-aminolevulinic-acid-induced protoporphyrin IX in medicine: a review of multifaceted, ubiquitous, molecular diagnostic, therapeutic, and theranostic opportunities. J Biomed Opt. 2025;30(Suppl 3):S34112.","journal-title":"J Biomed Opt"},{"key":"3326_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126478","author":"Y Harada","year":"2022","unstructured":"Harada Y, et al. 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence imaging for tumor detection: recent advances and challenges. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126478.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3326_CR73","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/php.13091","volume":"95","author":"P Palasuberniam","year":"2019","unstructured":"Palasuberniam P, et al. Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine. Photochem Photobiol. 2019;95(4):1052\u20139.","journal-title":"Photochem Photobiol"},{"issue":"8","key":"3326_CR74","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41416-019-0516-4","volume":"121","author":"K McNicholas","year":"2019","unstructured":"McNicholas K, MacGregor MN, Gleadle JM. order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? Br J Cancer. 2019;121(8):631\u20139.","journal-title":"Br J Cancer"},{"key":"3326_CR75","doi-asserted-by":"publisher","first-page":"112342","DOI":"10.1016\/j.biopha.2021.112342","volume":"144","author":"M Czarnecka-Czapczynska","year":"2021","unstructured":"Czarnecka-Czapczynska M, et al. The role of photodynamic therapy in breast cancer - A review of in vitro research. Biomed Pharmacother. 2021;144:112342.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3326_CR76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10103-024-04141-9","volume":"39","author":"B Erk","year":"2024","unstructured":"Erk B, Kamanli AF, Guney G, Eskiler. The therapeutic efficacy of 5-ALA based photodynamic therapy and chemotherapy combination in triple negative breast cancer cells. Lasers Med Sci. 2024;39(1):191.","journal-title":"Lasers Med Sci"},{"key":"3326_CR77","doi-asserted-by":"publisher","first-page":"103998","DOI":"10.1016\/j.pdpdt.2024.103998","volume":"45","author":"ES Chu","year":"2024","unstructured":"Chu ES, Wu RW, Huang Z. Potential therapeutic efficacy of photodynamic therapy on female hormonal-dependent cancers in a hormonal simulated microenvironment. Photodiagnosis Photodyn Ther. 2024;45:103998.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3326_CR78","doi-asserted-by":"publisher","first-page":"104186","DOI":"10.1016\/j.pdpdt.2024.104186","volume":"46","author":"KCN Cheung","year":"2024","unstructured":"Cheung KCN, et al. Potential therapeutic efficacy of Photodynamic Therapy on triple negative breast cancer in hormonal microenvironment. Photodiagn Photodyn Ther. 2024;46:104186.","journal-title":"Photodiagn Photodyn Ther"},{"key":"3326_CR79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.exer.2014.04.011","volume":"124","author":"K Brodowska","year":"2014","unstructured":"Brodowska K, et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014;124:67\u201373.","journal-title":"Exp Eye Res"},{"issue":"2","key":"3326_CR80","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1517\/14656566.2.2.351","volume":"2","author":"SB Brown","year":"2001","unstructured":"Brown SB, Mellish KJ. Verteporfin: a milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother. 2001;2(2):351\u201361.","journal-title":"Expert Opin Pharmacother"},{"key":"3326_CR81","doi-asserted-by":"publisher","first-page":"1188087","DOI":"10.3389\/fimmu.2023.1188087","volume":"14","author":"SM Banerjee","year":"2023","unstructured":"Banerjee SM, et al. Combination of verteporfin-photodynamic therapy with 5-aza-2\u2019-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer. Front Immunol. 2023;14:1188087.","journal-title":"Front Immunol"},{"issue":"4","key":"3326_CR82","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/17435889.2025.2456450","volume":"20","author":"H Yu","year":"2025","unstructured":"Yu H, et al. Chlorin e6: a promising photosensitizer of anti-tumor and anti-inflammatory effects in PDT. Nanomed (Lond). 2025;20(4):389\u2013400.","journal-title":"Nanomed (Lond)"},{"issue":"2","key":"3326_CR83","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1021\/acsabm.2c00891","volume":"6","author":"A Hak","year":"2023","unstructured":"Hak A, et al. Chlorin e6: A Promising Photosensitizer in Photo-Based Cancer Nanomedicine. ACS Appl Bio Mater. 2023;6(2):349\u201364.","journal-title":"ACS Appl Bio Mater"},{"issue":"1\u20133","key":"3326_CR84","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1011-1344(99)00130-X","volume":"53","author":"B Cunderlikova","year":"1999","unstructured":"Cunderlikova B, Gangeskar L, Moan J. Acid-base properties of chlorin e6: relation to cellular uptake. J Photochem Photobiol B. 1999;53(1\u20133):81\u201390.","journal-title":"J Photochem Photobiol B"},{"issue":"24","key":"3326_CR85","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.3889\/oamjms.2019.838","volume":"7","author":"HTH Bui","year":"2019","unstructured":"Bui HTH, et al. Transformation Chlorophyll a of Spirulina platensis to Chlorin e6 Derivatives and Several Applications. Open Access Maced J Med Sci. 2019;7(24):4372\u20137.","journal-title":"Open Access Maced J Med Sci"},{"issue":"2","key":"3326_CR86","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10103-020-03035-w","volume":"36","author":"P Huang","year":"2021","unstructured":"Huang P, et al. Photodynamic treatment with purpurin 18 effectively inhibits triple negative breast cancer by inducing cell apoptosis. Lasers Med Sci. 2021;36(2):339\u201347.","journal-title":"Lasers Med Sci"},{"key":"3326_CR87","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ultsonch.2014.10.027","volume":"23","author":"P Wang","year":"2015","unstructured":"Wang P, et al. Anti-metastatic and pro-apoptotic effects elicited by combination photodynamic therapy with sonodynamic therapy on breast cancer both in vitro and in vivo. Ultrason Sonochem. 2015;23:116\u201327.","journal-title":"Ultrason Sonochem"},{"key":"3326_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050576","author":"MF Isaac-Lam","year":"2024","unstructured":"Isaac-Lam MF. Chlorin conjugates in photodynamic chemotherapy for triple-negative breast cancer. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17050576.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"3326_CR89","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.apsb.2023.11.030","volume":"14","author":"LC Nene","year":"2024","unstructured":"Nene LC, Abrahamse H. Design consideration of phthalocyanines as sensitizers for enhanced sono-photodynamic combinatorial therapy of cancer. Acta Pharm Sin B. 2024;14(3):1077\u201397.","journal-title":"Acta Pharm Sin B"},{"key":"3326_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122057","author":"LR Carobeli","year":"2021","unstructured":"Carobeli LR, et al. Phthalocyanine and its formulations: a promising photosensitizer for cervical cancer phototherapy. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13122057.","journal-title":"Pharmaceutics"},{"issue":"6","key":"3326_CR91","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.chemosphere.2013.05.032","volume":"93","author":"D Jancula","year":"2013","unstructured":"Jancula D, Marsalek B, Babica P. Photodynamic effects of 31 different phthalocyanines on a human keratinocyte cell line. Chemosphere. 2013;93(6):870\u20134.","journal-title":"Chemosphere"},{"key":"3326_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.poly.2023.116617","volume":"245","author":"\u015e Do\u011fan","year":"2023","unstructured":"Do\u011fan \u015e, et al. Photodynamic therapy potential of cobalt phthalocyanine in triple-negative breast cancer. Polyhedron. 2023;245:116617.","journal-title":"Polyhedron"},{"key":"3326_CR93","first-page":"101686","volume":"38","author":"BC Casali","year":"2024","unstructured":"Casali BC, et al. Blockage of alphavbeta3 integrin in 3D culture of triple-negative breast cancer and endothelial cells inhibits migration and discourages endothelial-to-mesenchymal plasticity. Biochem Biophys Rep. 2024;38:101686.","journal-title":"Biochem Biophys Rep"},{"issue":"3","key":"3326_CR94","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/ijms23031745","volume":"23","author":"BC Casali","year":"2022","unstructured":"Casali BC et al. The effects of alphavbeta3 integrin blockage in breast tumor and endothelial cells under hypoxia in vitro. Int J Mol Sci. 2022;23(3):1745.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3326_CR95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-022-00906-2","volume":"7","author":"R Li","year":"2022","unstructured":"Li R, et al. Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer. Signal Transduct Target Therapy. 2022;7(1):64.","journal-title":"Signal Transduct Target Therapy"},{"key":"3326_CR96","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.cbpa.2023.102289","volume":"74","author":"H Kobayashi","year":"2023","unstructured":"Kobayashi H, Choyke PL, Ogawa M. The chemical basis of cytotoxicity of silicon-phthalocyanine-based near infrared photoimmunotherapy (NIR-PIT) and its implications for treatment monitoring. Curr Opin Chem Biol. 2023;74:102289.","journal-title":"Curr Opin Chem Biol"},{"issue":"8","key":"3326_CR97","doi-asserted-by":"publisher","first-page":"e0136829","DOI":"10.1371\/journal.pone.0136829","volume":"10","author":"T Nagaya","year":"2015","unstructured":"Nagaya T, et al. Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS ONE. 2015;10(8):e0136829.","journal-title":"PLoS ONE"},{"issue":"2","key":"3326_CR98","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","volume":"136","author":"H Masuda","year":"2012","unstructured":"Masuda H, et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"3326_CR99","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.pdpdt.2018.09.006","volume":"24","author":"J Zhang","year":"2018","unstructured":"Zhang J, et al. Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer. Photodiagnosis Photodyn Ther. 2018;24:185\u201391.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3326_CR100","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.actbio.2017.03.012","volume":"54","author":"L Yang","year":"2017","unstructured":"Yang L, et al. Multilayer photodynamic therapy for highly effective and safe cancer treatment. Acta Biomater. 2017;54:271\u201380.","journal-title":"Acta Biomater"},{"issue":"11","key":"3326_CR101","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1158\/1535-7163.MCT-09-0448","volume":"8","author":"Z Qamri","year":"2009","unstructured":"Qamri Z, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009;8(11):3117\u201329.","journal-title":"Mol Cancer Ther"},{"key":"3326_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154356","volume":"105","author":"N Choudhary","year":"2022","unstructured":"Choudhary N, et al. Hypericin and its anticancer effects: from mechanism of action to potential therapeutic application. Phytomedicine. 2022;105:154356.","journal-title":"Phytomedicine"},{"issue":"2","key":"3326_CR103","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/ijms11020562","volume":"11","author":"A Karioti","year":"2010","unstructured":"Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci. 2010;11(2):562\u201394.","journal-title":"Int J Mol Sci"},{"key":"3326_CR104","first-page":"580","volume":"25","author":"S Zeng","year":"2023","unstructured":"Zeng S, et al. Activation of pyroptosis by specific organelle-targeting photodynamic therapy to amplify immunogenic cell death for anti-tumor immunotherapy. Bioact Mater. 2023;25:580\u201393.","journal-title":"Bioact Mater"},{"issue":"6","key":"3326_CR105","doi-asserted-by":"publisher","first-page":"e697","DOI":"10.1038\/cddis.2013.219","volume":"4","author":"M Barathan","year":"2013","unstructured":"Barathan M, et al. Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases. Cell Death Dis. 2013;4(6):e697.","journal-title":"Cell Death Dis"},{"key":"3326_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.01.042","author":"C Liang","year":"2025","unstructured":"Liang C, et al. Hypericin photoactivation induces triple-negative breast cancer cells pyroptosis by targeting the ROS\/CALR\/Caspase-3\/GSDME pathway. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.01.042.","journal-title":"J Adv Res"},{"key":"3326_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101781","volume":"69","author":"SO Vasudevan","year":"2023","unstructured":"Vasudevan SO, Behl B, Rathinam VA. Pyroptosis-induced inflammation and tissue damage. Semin Immunol. 2023;69:101781.","journal-title":"Semin Immunol"},{"issue":"3","key":"3326_CR108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5662\/wjm.v13.i3.29","volume":"13","author":"D Mukherjee","year":"2023","unstructured":"Mukherjee D, Krishnan A. Therapeutic potential of curcumin and its nanoformulations for treating oral cancer. World J Methodol. 2023;13(3):29\u201345.","journal-title":"World J Methodol"},{"key":"3326_CR109","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fphar.2020.00487","volume":"11","author":"A Karthikeyan","year":"2020","unstructured":"Karthikeyan A, Senthil N, Min T. Nanocurcumin: A Promising Candidate for Therapeutic Applications. Front Pharmacol. 2020;11:487.","journal-title":"Front Pharmacol"},{"key":"3326_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61060981","author":"AM Trofin","year":"2025","unstructured":"Trofin AM, et al. From nature to nanomedicine: enhancing the antitumor efficacy of rhein, curcumin, and resveratrol. Medicina (Kaunas, Lithuania). 2025. https:\/\/doi.org\/10.3390\/medicina61060981.","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"3326_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12010007","author":"GM Hashim","year":"2024","unstructured":"Hashim GM, et al. Plant-derived anti-cancer therapeutics and biopharmaceuticals. Bioengineering (Basel). 2024. https:\/\/doi.org\/10.3390\/bioengineering12010007.","journal-title":"Bioengineering (Basel)"},{"issue":"1","key":"3326_CR112","doi-asserted-by":"publisher","first-page":"21206","DOI":"10.1038\/s41598-020-78241-1","volume":"10","author":"A Ashkbar","year":"2020","unstructured":"Ashkbar A, et al. Treatment of breast cancer in vivo by dual photodynamic and photothermal approaches with the aid of curcumin photosensitizer and magnetic nanoparticles. Sci Rep. 2020;10(1):21206.","journal-title":"Sci Rep"},{"issue":"1","key":"3326_CR113","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40824-023-00447-x","volume":"27","author":"X Liang","year":"2023","unstructured":"Liang X, et al. Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer. Biomaterials Res. 2023;27(1):120.","journal-title":"Biomaterials Res"},{"key":"3326_CR114","doi-asserted-by":"publisher","first-page":"0277","DOI":"10.34133\/research.0277","volume":"7","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al. Traceable lactate-fueled self-acting photodynamic therapy against triple-negative breast cancer. Research. 2024;7:0277.","journal-title":"Research"},{"key":"3326_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100577","volume":"19","author":"C Yu","year":"2023","unstructured":"Yu C, et al. A photodynamic-mediated glutamine metabolic intervention nanodrug for triple negative breast cancer therapy. Mater Today Bio. 2023;19:100577.","journal-title":"Mater Today Bio"},{"key":"3326_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101136","volume":"61","author":"H Choi","year":"2025","unstructured":"Choi H, et al. Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export. Neoplasia. 2025;61:101136.","journal-title":"Neoplasia"},{"issue":"1","key":"3326_CR117","doi-asserted-by":"publisher","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","volume":"17","author":"Z Wang","year":"2020","unstructured":"Wang Z, Jiang Q, Dong C. Metabolic reprogramming in triple-negative breast cancer. Cancer Biol Med. 2020;17(1):44\u201359.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"3326_CR118","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.7150\/thno.124154","volume":"16","author":"H Yang","year":"2026","unstructured":"Yang H, et al. Glutathione-depleting photosensitizers for tumor-specific imaging and pyroptosis-driven photodynamic therapy. Theranostics. 2026;16(4):1818\u201332.","journal-title":"Theranostics"},{"key":"3326_CR119","doi-asserted-by":"publisher","first-page":"112956","DOI":"10.1016\/j.colsurfb.2022.112956","volume":"220","author":"Z Huang","year":"2022","unstructured":"Huang Z, et al. Mitochondria-targeted photosensitizer based nanoplatform loading glutathione inhibitor for enhanced breast cancer photodynamic therapy. Colloids Surf B. 2022;220:112956.","journal-title":"Colloids Surf B"},{"issue":"18","key":"3326_CR120","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.21037\/atm-20-5704","volume":"8","author":"X Pei","year":"2020","unstructured":"Pei X, et al. Metformin and oxyphotodynamic therapy as a novel treatment approach for triple-negative breast cancer. Annals Translational Med. 2020;8(18):1138.","journal-title":"Annals Translational Med"},{"issue":"2","key":"3326_CR121","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s10103-021-03367-1","volume":"37","author":"A Magnussen","year":"2022","unstructured":"Magnussen A, et al. Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy. Lasers Med Sci. 2022;37(2):1155\u201366.","journal-title":"Lasers Med Sci"},{"issue":"4","key":"3326_CR122","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"3326_CR123","doi-asserted-by":"crossref","unstructured":"Kroemer G. [Mitochondrial control of apoptosis]. Bull Acad Natl Med, 2001. 185(6): pp. 1135-42; discussion 1143.","DOI":"10.1016\/S0001-4079(19)34476-0"},{"issue":"9","key":"3326_CR124","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","volume":"11","author":"BE Burdette","year":"2021","unstructured":"Burdette BE, et al. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768\u201382.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"3326_CR125","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1042\/EBC20170021","volume":"61","author":"M Zachari","year":"2017","unstructured":"Zachari M, Ganley IG. The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 2017;61(6):585\u201396.","journal-title":"Essays Biochem"},{"key":"3326_CR126","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41419-024-06947-5","volume":"15","author":"S Schuermans","year":"2024","unstructured":"Schuermans S, Kestens C, Marques PE. Systemic mechanisms of necrotic cell debris clearance. Cell Death Dis. 2024;15:557. https:\/\/doi.org\/10.1038\/s41419-024-06947-5","journal-title":"Cell Death Dis"},{"key":"3326_CR127","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fonc.2017.00314","volume":"7","author":"T Nagaya","year":"2017","unstructured":"Nagaya T, et al. Fluorescence-Guided Surgery. Front Oncol. 2017;7:314.","journal-title":"Front Oncol"},{"issue":"18","key":"3326_CR128","doi-asserted-by":"publisher","first-page":"9054","DOI":"10.7150\/thno.62479","volume":"11","author":"P Sarbadhikary","year":"2021","unstructured":"Sarbadhikary P, George BP, Abrahamse H. Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer. Theranostics. 2021;11(18):9054\u201388.","journal-title":"Theranostics"},{"key":"3326_CR129","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302547","author":"SR Adapa","year":"2024","unstructured":"Adapa SR, et al. Porphyrin overdrive rewires cancer cell metabolism. Life Sci Alliance. 2024. https:\/\/doi.org\/10.26508\/lsa.202302547.","journal-title":"Life Sci Alliance"},{"issue":"6","key":"3326_CR130","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3171\/2017.1.JNS162061","volume":"128","author":"DW Roberts","year":"2018","unstructured":"Roberts DW, et al. Red-light excitation of protoporphyrin IX fluorescence for subsurface tumor detection. J Neurosurg. 2018;128(6):1690\u20137.","journal-title":"J Neurosurg"},{"issue":"1","key":"3326_CR131","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13058-021-01442-7","volume":"23","author":"K Ottolino-Perry","year":"2021","unstructured":"Ottolino-Perry K, et al. Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial. Breast Cancer Res. 2021;23(1):72.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3326_CR132","doi-asserted-by":"publisher","first-page":"13298","DOI":"10.1038\/srep13298","volume":"5","author":"P Palasuberniam","year":"2015","unstructured":"Palasuberniam P, et al. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy. Sci Rep. 2015;5(1):13298.","journal-title":"Sci Rep"},{"issue":"3","key":"3326_CR133","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s12282-020-01210-z","volume":"28","author":"M Nedeljkovic","year":"2021","unstructured":"Nedeljkovic M, et al. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. Breast Cancer. 2021;28(3):727\u201336.","journal-title":"Breast Cancer"},{"issue":"11","key":"3326_CR134","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.123.001582","volume":"52","author":"Q Qi","year":"2024","unstructured":"Qi Q, et al. Roles of the ABCG2 Transporter in Protoporphyrin IX Distribution and Toxicity. Drug Metab Dispos. 2024;52(11):1201\u20137.","journal-title":"Drug Metab Dispos"},{"key":"3326_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115851","volume":"217","author":"S Chandratre","year":"2023","unstructured":"Chandratre S, et al. Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy. Biochem Pharmacol. 2023;217:115851.","journal-title":"Biochem Pharmacol"},{"key":"3326_CR136","doi-asserted-by":"publisher","first-page":"13298","DOI":"10.1038\/srep13298","volume":"5","author":"P Palasuberniam","year":"2015","unstructured":"Palasuberniam P, et al. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy. Sci Rep. 2015;5:13298.","journal-title":"Sci Rep"},{"issue":"2","key":"3326_CR137","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/ijpm.ijpm_437_21","volume":"66","author":"R Tomar","year":"2023","unstructured":"Tomar R, et al. Role of CD44 as cancer stem cell marker in triple-negative breast cancer and its association with histological grade and angiogenesis. Indian J Pathol Microbiol. 2023;66(2):258\u201363.","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"3326_CR138","doi-asserted-by":"publisher","first-page":"27871","DOI":"10.1038\/srep27871","volume":"6","author":"J Jin","year":"2016","unstructured":"Jin J, et al. Phototheranostics of CD44-positive cell populations in triple negative breast cancer. Sci Rep. 2016;6(1):27871.","journal-title":"Sci Rep"},{"issue":"2","key":"3326_CR139","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7150\/ntno.34921","volume":"3","author":"D Reichel","year":"2019","unstructured":"Reichel D, et al. Tumor-Activatable Clinical Nanoprobe for Cancer Imaging. Nanotheranostics. 2019;3(2):196\u2013211.","journal-title":"Nanotheranostics"},{"issue":"5","key":"3326_CR140","first-page":"656","volume":"5","author":"J Choi","year":"2015","unstructured":"Choi J, Kim H, Choi Y. Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic\/chemo dual therapy of triple-negative breast cancer. Quant Imaging Med Surg. 2015;5(5):656\u201364.","journal-title":"Quant Imaging Med Surg"},{"key":"3326_CR141","doi-asserted-by":"publisher","first-page":"107527","DOI":"10.1016\/j.ultsonch.2025.107527","volume":"121","author":"MY Wang","year":"2025","unstructured":"Wang MY, et al. Enhancing the efficacy of sonodynamic therapy through modulation of autophagy. Ultrason Sonochem. 2025;121:107527.","journal-title":"Ultrason Sonochem"},{"issue":"1","key":"3326_CR142","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/ijms27010450","volume":"27","author":"CH Lee","year":"2025","unstructured":"Lee CH et al. Overcoming therapeutic resistance in triple-negative breast cancer: targeting the undrugged kinome. Int J Mol Sci. 2025;27(1):450.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3326_CR143","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/carcin\/bgs167","volume":"33","author":"YY Park","year":"2012","unstructured":"Park YY, et al. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012;33(10):1843\u201353.","journal-title":"Carcinogenesis"},{"issue":"5","key":"3326_CR144","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1096\/fj.201701157R","volume":"32","author":"T Miran","year":"2018","unstructured":"Miran T, et al. Modulation of glutathione promotes apoptosis in triple-negative breast cancer cells. FASEB J. 2018;32(5):2803\u201313.","journal-title":"FASEB J"},{"issue":"8","key":"3326_CR145","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1039\/c4pp00495g","volume":"14","author":"BQ Spring","year":"2015","unstructured":"Spring BQ, et al. The role of photodynamic therapy in overcoming cancer drug resistance. Photochem Photobiol Sci. 2015;14(8):1476\u201391.","journal-title":"Photochem Photobiol Sci"},{"key":"3326_CR146","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2147\/IJN.S449042","volume":"19","author":"Y Hu","year":"2024","unstructured":"Hu Y, et al. Combined Photosensitive Gene Therapy Effective Against Triple-Negative Breast Cancer in Mice Model. Int J Nanomed. 2024;19:1809\u201325.","journal-title":"Int J Nanomed"},{"key":"3326_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1681773","volume":"16","author":"Y Du","year":"2025","unstructured":"Du Y, et al. Research progress on the induction of immunogenic cell death in tumor immunotherapy using a sonodynamic therapy nanoparticle delivery system. Front Immunol. 2025;16:1681773.","journal-title":"Front Immunol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03326-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03326-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03326-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:03:31Z","timestamp":1788930211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03326-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":147,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3326"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03326-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"224"}}